BofA/Merrill Lynch Upgrades Edwards Lifesciences (EW) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Edwards Lifesciences Reports Second Quarter Results
July 26, 2016 4:15 PM EDTIRVINE, Calif., July 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2016.
Second Quarter Highlights:
Sales grew 23.1% to $759.3 million; underlying1 sales were up 21% Global Transcatheter Heart Valve Therapy (THVT) sales grew 48.7%; underlying grew 45% U.S. THVT sales were up 71.5%; underlying grew 66% GAAP EPS was $0.58, an increase of 13.7%; adjusted2 EPS grew 33% to $0.76 2016... More